Were the Disc Medicine (IRON) CFO’s share sales made under a trading plan?

Yes. The Form 4 notes the transactions were made under a Rule 10b5-1 trading plan . The plan was adopted on September 25, 2025, indicating the sales were pre-arranged according to that preset trading instruction framework.

Disc Medicine (IRON) CFO sells 6,657 shares under 10b5-1 plan

Q: How many Disc Medicine (IRON) shares did the CFO sell in this Form 4?

The CFO sold a total of 6,657 Disc Medicine shares . This included 6,257 shares sold on April 14, 2026, and 400 shares sold on April 13, 2026, all reported as open-market sales of common stock.

Q: At what prices did the Disc Medicine (IRON) CFO sell shares?

The CFO’s open-market sales were reported around $69 per share . On April 14, 2026, 6,257 shares sold at a weighted average of $69.2399 . On April 13, 2026, 400 shares sold at $69.00 per share.

Q: How many Disc Medicine (IRON) shares does the CFO hold after these sales?

After the reported transactions, the CFO directly holds 64,333 shares of Disc Medicine common stock. This post-transaction holding reflects both April 13 and April 14, 2026 open-market sales disclosed in the Form 4 filing.

Q: What price range is mentioned for the Disc Medicine (IRON) CFO’s April 14, 2026 sale?

The April 14, 2026 transaction used a weighted average price of $69.2399. Footnotes explain the 6,257 shares were sold in multiple trades at prices ranging from $69.07 to $69.43 , with detailed breakdowns available upon request.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Financial Officer Jean M. Franchi reported open-market sales of company common stock. On April 14, 2026, the CFO sold 6,257 shares at a weighted average price of $69.2399 per share. On April 13, 2026, the CFO sold an additional 400 shares at $69.00 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on September 25, 2025. Following the reported sales, the CFO directly holds 64,333 shares of Disc Medicine common stock.

Insider Trade Summary 10b5-1

Net Seller: 6,657 shares ($460,834)

Net Sell 2 txns

Insider Franchi Jean M.

Role Chief Financial Officer

Sold 6,657 shs ($461K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,257	$69.2399	$433K
Sale	Common Stock	400	$69.00	$28K

Holdings After Transaction: Common Stock — 64,333 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Key Figures

Shares sold 2026-04-14: 6,257 shares Weighted average price 2026-04-14: $69.2399 per share Shares sold 2026-04-13: 400 shares +4 more

7 metrics

Shares sold 2026-04-14 6,257 shares Open-market sale of common stock on April 14, 2026

Weighted average price 2026-04-14 $69.2399 per share Price for 6,257 sold shares on April 14, 2026

Shares sold 2026-04-13 400 shares Open-market sale of common stock on April 13, 2026

Sale price 2026-04-13 $69.00 per share Price for 400 sold shares on April 13, 2026

Total shares sold 6,657 shares Combined April 13–14, 2026 open-market sales

Shares held after transactions 64,333 shares Direct common stock holdings following reported sales

April 14 price range $69.07–$69.43 per share Range of individual trade prices within April 14, 2026 sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average price, Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"ranges set forth in footnote (2) to this Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 04:53 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Franchi Jean M.

(Last)

(First)

(Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/13/2026		S⁽¹⁾		400	D	$69	70,590	D
Common Stock	04/14/2026		S⁽¹⁾		6,257	D	$69.2399⁽²⁾	64,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	By: /s/ Rahul Khara, as Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many Disc Medicine (IRON) shares did the CFO sell in this Form 4?

The CFO sold a total of 6,657 Disc Medicine shares. This included 6,257 shares sold on April 14, 2026, and 400 shares sold on April 13, 2026, all reported as open-market sales of common stock.

At what prices did the Disc Medicine (IRON) CFO sell shares?

The CFO’s open-market sales were reported around $69 per share. On April 14, 2026, 6,257 shares sold at a weighted average of $69.2399. On April 13, 2026, 400 shares sold at $69.00 per share.

How many Disc Medicine (IRON) shares does the CFO hold after these sales?

After the reported transactions, the CFO directly holds 64,333 shares of Disc Medicine common stock. This post-transaction holding reflects both April 13 and April 14, 2026 open-market sales disclosed in the Form 4 filing.

What price range is mentioned for the Disc Medicine (IRON) CFO’s April 14, 2026 sale?

The April 14, 2026 transaction used a weighted average price of $69.2399. Footnotes explain the 6,257 shares were sold in multiple trades at prices ranging from $69.07 to $69.43, with detailed breakdowns available upon request.